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Effect of whole body vibration in Parkinson's disease: A 
controlled study  




In the search of new strategies to improve the quality of life of Parkinson's disease patients, recent work has reported 
an amelioration of Parkinsonian symptoms using Whole Body Vibration (WBV). A double-blinded, placebo 
controlled design was used to evaluate the effect of a 12 WBV sessions-programme on a number of motor and 
clinical tests in 23 Parkinson's disease patients. Patients were assigned to one of two groups, one receiving WBV and 
the other a placebo group. At the end of the programme as well as during intra-session evaluation, there was no 
difference between the experimental (vibration) and placebo groups in any outcomes. These results suggest that 
reported benefits of vibration are due to a placebo response.  
The use of vibrating platforms has been introduced in the sports medicine aiming to improve strength 
in disciplines requiring powerful muscle contractions, though its effectiveness has not yet been clearly 
demonstrated.1 Recently, this technique has been used in Parkinson's disease patients, with some 
promising results.2–4 Haas et al.3 have reported an improvement UPDRS scores (rigidity and tremor) in a 
group of patients after undergoing a single session of whole body vibration (WBV). Previous reports by 
the same group,2 showed a significant improvement in postural stability on an unstable platform after one 
session of WBV. Both studies were performed by applying five sets of 60 seconds each, at 6 Hz, 
employing stochastic vibration which was one of the key features advocated by the authors.5 However, 
more recently, significant effects on Parkinsonian patients have been reported using nonstochastic 
vibration.4 These authors showed the effect of 25 Hz stimulation (twice per day, 15 min./each) for 3 
weeks which produced an improvement in a set of motor tests (Tinetti balance score,6 gait velocity, stand-
walk-sit test, UPDRSIII), although similar results were seen with conventional rehabilitation therapy 
(relaxation, occupational therapy, etc.). However, the results by Ebersbach et al.4 seem important, since, 
besides the acute effects reported previously,2, 3 they appeared to show long lasting effects. Improvement 
after the end of the 3 week programme lasted at least 4 more weeks. Nevertheless, as stated by the 
authors,2–4 the lack of a control (placebo) is a weakness of these studies. The effect of placebo on different 
pathologic conditions is well know, and it seems Parkinsonian patients are especially affected,7, 8 chiefly 
when a reward is expected (improvement in clinical symptoms due to a new treatment, for instance). 
This study aims to evaluate the effect of WBV on motor symptoms on Parkinson's disease patients, 
while controlling for the placebo effect. 
METHODS 
Patients 
A total of 29 Parkinson's disease patients, belonging to Asociación Parkinson Bueu in Spain were 
recruited for the study. To take part in the study, patients had to match the primary diagnosis of 
Parkinson's disease (PD) (based on medical records following established diagnostic criteria); lack of 
dementia (MMSE ≥ 24); lack of artromuscular deficit or joint prosthesis; and be able to cope with OFF 
periods (n = 23). Patients were required to complete all sessions and could not change their regime of 
medication throughout the study. Patients were allocated to either experimental or placebo group based 
upon an ABBA (A=experimental; B=placebo) distribution model, using their times to complete the Gait 
test. Although initial allocations placed 12 patients in the experimental group and 11 in the placebo group, 
which were not significantly different in any pretest measure, 2 patients withdrew from the study. Pretest 
data for the remaining 10 experimental and 11 placebo patients were still not significantly different (P > 
0.05), neither their weight, height, trochanteral height, and acromion-finger length (Table 1). 
TABLE 1. Subjects 
Patient (Group) Sex Age Weight (kg) Height (m) Arm length (m) Trochanteral height (m) 
1(Placebo) F 65 66 1.55 0.73 0.75 
2(Placebo) M 75 64 1.59 0.77 0.79 
3(Placebo) F 58 87 1.57 0.77 0.83 
4(Placebo) F 73 68 1.60 0.76 0.78 
5(Placebo) M 59 81 1.67 0.74 0.80 
6(Placebo) M 72 87 1.80 0.81 0.85 
7(Placebo) M 67 75 1.70 0.78 0.85 
8(Placebo) F 65 75 1.65 0.75 0.81 
9(Placebo) M 66 74 1.73 0.79 0.83 
10(Placebo) F 62 78 1.70 0.77 0.83 
11(Placebo) M 70 70 1.67 0.79 0.83 
Group Mean  66.55 75.00 1.66 0.77 0.81 
 (±sd)  (±5.57) (±7.81) (±0.08) (±0.02) (±0.03) 
1(Experimental) F 67 68 1.47 0.65 0.74 
2(Experimental) M 79 72 1.61 0.71 0.84 
3(Experimental) F 74 86 1.62 0.72 0.84 
4(Experimental) F 49 75 1.53 0.71 0.83 
5(Experimental) M 78 68 1.61 0.71 0.83 
6(Experimental) M 79 71 1.63 0.74 0.84 
7(Experimental) M 62 79 1.71 0.82 0.85 
8(Experimental) M 55 67 1.66 0.78 0.85 
9(Experimental) F 55 63 1.50 0.71 0.81 
10(Experimental) M 71 83 1.72 0.84 0.91 
Group Mean  66.90 73.20 1.61 0.74 0.83 
 (±sd)  (±11.11) (±7.45) (±0.08) (±0.06) (±0.04) 





The experimental group received 12 stimulation sessions over 5 weeks, on nonconsecutive days. 
Based on previous studies reporting beneficial effects on Parkinsonian symptoms2, 3 the stimulation 
frequency was set at 6 Hz., and each patient underwent 5 sets of stimulation of 1 min each, with an 
interset rest period of 1 min. During stimulation patients were asked to stand on the vibrating platform, 
with their feet separated at a stable and comfortable position, and with the knees slightly bent. 
For the placebo condition patients adopted the same position but vibration was not applied. Instead 
placebo patients were required to try to stay as still as they could, trying to minimize hip oscillation, 
yielding the same amount of weight of both feet. 
All other physical therapies usually undergone by the patients were cancelled during the duration of 
this study. Patients took their medication as usual, and stimulation session started 30–45 min after dose 
intake (when patients confirmed ON-periods). 
Evaluation 
 
We assessed the effect of vibration through two different sets of tests, one to test the effectiveness of the 
whole programme, and other measuring the acute effect of the different sessions (intra-session 
evaluation), see Table 2.  
TABLE 2. Evaluation protocol 
Preprogramme OFF-periods Stimulation programme (sessions) ON-periods Postprogramme OFF-periods 
   
Gait, Funct Reach, Pegboard, UPDRS, 
BergBalance 1
st 2nd …..12th Gait, Funct Reach,Pegboard, UPDRS, BergBalance 
 
Timed Up and Go, and Functional 
Reach: everyday before and after 
stimulation 
 
 Pegboard, at the 1st, 6th, and 12th sessions, before and after stimulation  
 PDQ-39, before the 1
st and after the 12th 
sessions  
   
 
Evaluation of the Effect of the Programme. Evaluation was carried out twice, two days before 
beginning and 2 days after the end of the intervention period respectively. PD patients were evaluated 
during their OFF-periods (>12 hr withholding medication); the tests performed were the following: Gait, 
Pegboard, Functional Reach (FR), UPDRS, and Berg Balance Test (BBT). In addition the Parkinson's 
disease questionnaire (PDQ-39) was evaluated also, but during ON periods. 
 
Intra-Session Evaluation. In addition to the comparisons made before and after the programme, we 
performed a series of intra-session evaluations, to know the acute effect of stimulation, so that a number 
of tests (see Table 2) were carried out just before and after stimulation. The Timed-up-and-go test (TUG), 
and the FR were tested every day. Hand dexterity (Pegboard) were performed at the first, sixth and last 
stimulation session. For intra-session evaluation patients were evaluated during ON-periods. 
All evaluations were performed by researchers blind to protocol and group assignment. 
 
Evaluation Tests. Gait: Subjects had to walk along a corridor, turn (U turn), and come back (see Fig. 
1a); subjects performed this task three times, with a rest of 2 min. The instruction given was “walk along 
the corridor as you normally do, turn around the object at the end of the corridor, come back and touch 
this button on the wall.” 
 
 
FIG 1. (a) Representation of the task carried out by patients during the gait 
test, (b) Anthropometer, and (c) Representation of the task performed 
during the Functional Reach. 
 
  
Functional Reach: Subjects had to displace the stick attached to the anthropometer as far as they 
could, pushing with their fist, without bending the knees or lifting the heels (Fig. 1b,c). Each subject did 
so three times for each arm, with a rest of 30 S between trails. The distance between the initial and the 
final position was taken as the functional reaching distance. 
Berg Balance Test: Briefly, the BBT9 is a 14-item scale widely used for assessing balance. The items 
are scored from 0 to 4 on the basis of the ability to complete a task, the higher the score the more 
independently performed the tasks. 
UPDRS: The total score and the motor section of the scale were taking into account. 
Purdue Pegboard Test: This was used to test hand dexterity—subjects had to place as many pegs 
(small steel rods) as possible, sequentially into a row of holes, within 30 S, and the number of pegs were 
registered. Subjects performed this task three times for each hand. 
PDQ-39: PDQ-3910 measures quality of life in Parkinsonian patients. It has 39 items to be rated (0–4), 
the higher the score the poorer quality of life. 
Timed up and go test: Briefly, for the TUG, patients are seated on a chair and once commanded, they 
had to stand up, walk at their preferred walking pattern for 3 m, turn, come back, and sit down on the 
chair again.11 The time taken was recorded with a stopwatch. Patients performed this task three times. 
Subjects gave their informed consent to the experimental procedure, conformed to the standards set by 
the Declaration of Helsinki. Procedure was approved by the University of A Coruña Ethics Committee. 
 
Apparatus. For gait evaluation recording system consisted of a series of footswitches worn as insoles 
in the shoes. The footswitches were connected to a radio-transmitter attached to the subjects' belt. Data 
(sampled at 1 KHz.) were sent to a receiver unit connected to the computer. This configuration allowed 
the stride cycle time to be registered. Two photocells, placed 4.50 m apart, were connected to the 
recording system. 
For the FR test an Harpenden Anthropometer (Holtain Ltd), calibrated to the nearest millimetre, was 
mounted on a tripod (see Fig. 1b,c), so that the functional reaching distance could be obtain from the 
difference between the starting and the end positions of the moveable part of the anthropometer. 
For WBV stimulation was provided by means of a vibrating platform (Fit Massage, PYC Fitness 
International Inc), commercially available in various countries. The vibrating platform, configurable in 
frequency (up to 50 hz with an amplitude of 13 mm, model specifications), thrusts the right and left leg 
upward alternately (in concordance to previous studies, Ebersbach et al.4). 
 
Analyzed Variables. For the gait test, a number of kinematic variables were analyzed:  
 
–Velocity, it was calculated from the time consumed to cover the straight part of the task, data 
obtained from the photocells. 
–Cadence, it was calculated from data obtained through footswitches, corresponding to the straight 
part of the task. 
–Step amplitude, derived from the combination of velocity and cadence. 
–Turn time, obtained from the successive activation of the photocell at the end of the corridor (before 
and after the turn). 
–The CVstride-time, obtained from the footswitches data of the straight section, it was define defined as  
 
CV (%) = (sd/mean) x 100 
 
All the gait variables correspond to the mean of the tree trials. 
For the FR test, it was calculated the mean functional reaching distance obtained in the three trials. 
Scores from both arms were averaged. 
The scores from the BBT, PDQ-39 and UPDRS were introduced in the analysis. 
The mean number of pegs introduced into the holes in the three trials was the variable analyzed in the 
Purdue Pegboard test. Scores from both hands were averaged. 
The time consumed to complete the test was the variable analyzed in the TUG test (average from the 
three trials). 
Statistical Analysis 
To calculate differences between groups at the pretest a Students "t" for independent samples was 
applied for each variable. To measure the effect of the whole intervention programme a 2 × 2 ANOVA 
with repeated measures was performed for each of the variables analyzed Preprogramme vs. 
Postprogramme. The within subjects factor was Evaluation, with two levels (Pretest and Post-test); the 
between subjects factor was the Group (experimental or placebo). To know the intra-session effect a 
three-way ANOVA with repeated measures was performed. For TUG two within-subjects factor were 
defined, factor Session with 12 levels (each of the sessions), and factor Pre-Post with 2 levels (intra-
session evaluation, prestimulation and poststimulation); the between subjects factor was the Group 
(experimental or placebo). The same model was applied for the FR. For the Pegboard the model was the 
same as well, but factor Session had just 3 levels (1st, 6th, and 12th sessions). 
Normality of distribution was check by K-S test. Greenhouse-Geisser correction was applied when 
sphericity was violated. The SPSS package was used for statistical analysis. 
RESULTS 
Preprogramme vs. Postprogramme 
Characterization 
 
Before stimulation groups were equal in all the variables analyzed (see Table 3); for gait variables 
Students “t” for independent sample yielded no significant differences for any of the kinematics: velocity 
(t(19) = 0.139 P = 0.891), cadence (t(19) = 0.034 P = 0.974), step amplitude (t(19) = 0.233 P = 0.819), 
turn time (t(19) = 0.350 P = 0.730), and CVstride-time (t(19) = 0.067 P = 0.948). Also, the rest of the 
variables showed no differences between groups: UPDRS (t(19) = 1.466 P = 0.159); UPDRSIII (t(19) = 
1.826 P = 0.084); BBT (t(19) = 1.030 P = 0.316); number of pegs (t(19) = 0.557 P = 0.584); FR distance 
(t(19) = 0.435 P = 0.668) and PDQ39 (t(19) = 0.107 P = 0.916). 
TABLE 3. Differences between groups 
 Experimental Placebo 
At the preprogramme evaluation   
Gait   
Velocity (m/sc) 0.747 (±0.207) 0.734 (±0.212) 
Cadence (steps/sc) 1.781 (±0.166) 1.785 (±0.299) 
Step amplitude (m) 0.417 (±0.096) 0.408 (±0.083) 
Turn Time (scs) 2.041 (±1.175) 2.234 (±1.338) 
CVstride-time (%) 4.110 (±3.909) 4.021 (±1.994) 
UPDRS (score) 48.300 (±14.712) 58.090 (±15.776) 
UPDRSIII (score) 24.800 (±7.052) 30.454 (±7.118) 
Berg Balance (score) 46.200 (±5.223) 42.272 (±10.955) 
Functional Reach (mm) 207.258 (±74.701) 221.357 (±73.626) 
PegBoard (# rods) 7.010 (±2.378) 7.542 (±1.991) 
PDQ-39 (score) 49.500 (±15.714) 50.545 (±27.042) 
Before the 1st stimulation session   
TUG (scs) 13.344 (±3.155) 16.1927 (±7.599) 
Pegboard (# rods) 7.550 (±2.981) 7.8336 (±2.346) 
F. Reach (mm.) 235.067 (±76.269) 238.4091 (±68.654) 
   
 
No significant differences were yielded in any variable. 
 
Effect of the Stimulation 
 
A main effect of factor Evaluation was seen in a number of variables, showing significant change 
between Pre- and Post-test (Table 4). In the gait variables this was seen in the following: velocity [F(1,19) 
= 59.462 P ≤ 0.001]; step amplitude [F(1,19) = 34.277 P ≤ 0.001] and cadence [F(1,19) = 21.746 P ≤ 
0.001]. Conversely no main effect of factor Evaluation was seen in the CVstride-timeF(1,19) = 1.623 P = 
0.218; or the turn time F(1,19) = 1.847 P = 0.190. 
For the rest of the tests, the effect of the programme led FR to increase [F(1,19) = 65.229 P ≤ 0.001]; 
as well as to increase the number of pegs in the Pegboard test [F(1,19) = 25.617 P ≤ 0.001]; to reduce the 
total UPDRS score and the UPDRSIII score [F(1,19) = 32.903 P ≤ 0.001 and F(1,19) = 11.929 P = 0.003 
respectively) and to reduce the BBT score (F(1,19) = 22.052 P ≤ 0.001). PDQ-39 was not affected by the 
treatment (F(1,19) = 2.332 P = 0.143).  
TABLE 4. Effect of the stimulation programme 
  Pretest Posttest 
    
Gait    
Velocity (m/sc)  0.740 (±0.204) 0.900 (±0.216) P ≤ 0.001 
Cadence (steps/sc)  1.783 (±0.239) 1.889 (±0.241) P ≤ 0.001 
Step amplitude (m)  0.412 (±0.087) 0.474 (±0.088) P ≤ 0.001 
Turn Time (scs)  2.142 (±1.235) 1.884 (±0.844) 
CVstride-time(%)  4.063 (±2.977) 3.032 (±2.255) 
UPDRS (score)  53.428 (±15.714) 43.857 (±14.893) P ≤ 0.001 
UPDRSIII (score)  27.761 (±7.489) 23.000 (±6.752) P = 0.003 
Berg Balance (score)  44.142 (±8.736) 48.381 (±7.439) P ≤ 0.001 
F.Reach (mm) Experimental 207.258 (±74.701) 324.082 (±51.648) P ≤ 0.001 
 Placebo 221.357 (±73.626) 257.242 (±72.451) P = 0.013 
PegBoard (# rods)  7.289 (±2.145) 8.4338 (±2.389) P ≤ 0.001 
PDQ-39 (score)  50.047 (±21.841) 44.809 (±19.684) 
    
 
For the rest of the tests, the effect of the programme led FR to increase [F(1,19) = 65.229 P ≤ 0.001]; 
as well as to increase the number of pegs in the Pegboard test [F(1,19) = 25.617 P ≤ 0.001]; to reduce the 
total UPDRS score and the UPDRSIII score [F(1,19) = 32.903 P ≤ 0.001 and F(1,19) = 11.929 P = 0.003 
respectively) and to reduce the BBT score (F(1,19) = 22.052 P ≤ 0.001). PDQ-39 was not affected by the 
treatment (F(1,19) = 2.332 P = 0.143). 
However, the main outcome of this study is provided by the interaction Evaluation*Group—at this 
level no significant interaction was seen, showing the effect of treatment affected both groups equally. 
This occurred in all but one of the variables analyzed: velocity (F(1,19) = 1.648 P = 0.215; cadence 
(F(1,19) = 0.220 P = 0.644); amplitude (F(1,19) = 1.447 P = 0.244); CVstride-time (F(1,19) = 0.421 P = 
0.524); turn time (F(1,19) = 0.039 P = 0.846); BBT (F(1,19) = 2.387 P = 0.139); PDQ39 (F(1,19) = 
2.731 P = 0.115); Pegboard (F(1,19) = 1.792 P = 0.196); UPDRS and UPDRSIII (F(1,19) = 0.045 P = 
0.834 and F(1,19) = 0.662 P = 0.426 respectively). The only variable differentially affected by treatment 
was the FR distance, where a significant interaction was seen (F(1,19) = 18.324 P ≤ 0.001); however post 
hoc analysis showed that both groups, experimental and placebo, had increased (P ≤ 0.001 and P = 0.013 
respectively). 
No main effect for factor Group was seen at any variable; F(1,19) = 0.189 P = 0.669 for velocity; 
F(1,19) = 0.005 P = 0.947 for cadence; F(1,19) = 0.339 P = 0.567 for step amplitude; F(1,19) = 0.486 P 
= 0.494 for the CVstride-time; F(1,19) = 0.129 P = 0.723 for turn time; F(1,19) = 0.544 P = 0.470 for BBT; 
F(1,19) = 0.712 P = 0.409 for PDQ39; F(1,19) = 0.052 P = 0.822 for the Pegboard; F(1,19) = 2.247 P = 
0.150 and F(1,19) = 2.867 P = 0.107 for the UPDRS and UPDRSIII, and finally F(1,19) = 0.848 P = 
0.369 for the FR distance. 
Intra-session Evaluations 
The analysis of intra-sessions evaluation yielded similar results to the Preprogramme vs. 
Postprogramme analysis, even although the medication regime was different, OFF during Preprogramme 
vs. Postprogramme (except for PDQ-39), and ON during intra-sessions. 
Characterization 
 
Before the first stimulation session, both groups were comparable, as no significant differences were 
seen at any of the variables analyzed when compared by groups. 
For TUG t(19) = 1.100 & P = 0.285; for the Pegboard t(19) = 0.243 & P = 0.810; and for the FR 
t(19)=0.106 & P = 0.917 (see Table 3). 
Stimulation 
 
Stimulation produced interesting results. For the TUG a main effect of factor Session, 
F(2.765,52.529) = 5.389 & P = 0.003, showed patients changed their performance during successive 
days; however, the lack of interaction of Session*Group (F(2.765,52.529) = 1.091 P = 0.358) showed this 
effect was also seen in both groups, experimental and placebo, ruling out an effect of vibration on motor 
execution. Similarly, patients performed differently when we compared the execution before and after 
stimulation as factor Pre-Post showed a main effect F(1,19) = 5.758 & P = 0.027, but again this was seen 
in both groups of patients (experimental and placebo) as interaction between them was not significant 
(F(1,19) = 0.018 P = 0.894). The rest of the interactions were not significant (Fig. 2). 
 
 
FIG.2. Effect of stimulation on the TUG, Functional Reach, and Pegboard along the different sessions of the programme. Black 
bars represent evaluation prestimulation, and clear bars represent evaluation poststimulation, both within each session of the 
programme. 
For the Pegboard the only factor to have a main effect was factor Pre-Post F(1,19) = 18.100 P ≤ 
0.001, however, this again happened for both groups, with the interaction Pre-Post*Group not significant 
(F(1,19) = 0.807 P = 0.380) (Fig. 2). 
Finally, for the FR, the ANOVA showed the reaching distance was affected by the different sessions 
(factor Session) F(4.896,93.027) = 23.873 P ≤ 0.001. Also factor Pre-Post had a main effect F(1,19) = 
47.727 P ≤ 0.001, proving a different performance before or after the course of stimulation; this was also 
seen between the different sessions as the interaction Session*Pre-Post was also significant (F(11,209) = 
2.058 P = 0.025). However, the interaction Session*Pre-Post*Group was not significant, proving all 
changes in performance occurred in both groups (F(11,209) = 1.310 P = 0.221) (Fig. 2). 
Factor group was not significant at any variable; F(1,19) = 0.650 P = 0.430 for TUG; F(1,19) = 0.041 
P = 0.841 for the Pegboard; and F(1,19) = 0.235 P = 0.633 for the FR. 
DISCUSSION 
The main outcome of this study shows that a therapy based on WBV appears to affect Parkinsonian 
symptoms because of a significant placebo effect. In this study a set of motor tests mainly oriented to 
evaluate gait and balance, as well as other conditions such as hand dexterity, were equally affected by two 
protocols which differed only in the application of WBV. This was seen either before vs. after a 
rehabilitation programme lasting several weeks as well as when analysing the intra-session effect. Very 
few studies have assessed the effect of WBV on Parkinsonian motor signs—Turbanski et al.2 analyzed the 
effect of a single session of WBV on postural stability assessed in Parkinsonian patients with a 
modification of the Four Test Balance Scale on a movable and instable platform; these authors also tested 
a similar stimulation paradigm on tremor and rigidity assessed through UPDRS.3 In both cases an 
improvement in clinical features was described, which was attributed to WBV. In each case these studies 
included a control group, but the control groups were aware of their control status—in our study, the 
control group acted as test of the placebo effect—here placebo patients were treated identically to the 
experimental group, but, crucially, during “stimulation” the vibration platform was not switched on. This 
suggests that the "effect" of vibration, in a whole battery of clinical tests, using the same stimulation 
frequency and the same protocol (number of set and duration of each set),2, 3 either comparing intra-
session evaluations as the whole therapy, was no different to a placebo. This then suggests that the strong 
placebo effect seen in our study might also be responsible of results reported by Turbansky et al.2 and 
Hass et al.3 A point of difference, however, between our study and those of Turbansky et al.2 and Hass et 
al.3 is the nature of the stimulus—we used nonstochastic vibration, whereas they used stochastically 
derived vibration. However, Ebersbach et al.4 reported results in line with Turbansky et al.2 and Hass et 
al.,3 using nonstochastic vibration, just as we used in our study. Interestingly, Ebersbach et al.4 reported 
on the suitability of a therapy based on WBV for several days to improve gait and balance in a similar 
manner to other rehabilitative strategies, but here, again, the lack of control for placebo effect left a 
question open. Our study shows similar effects than those reported by Ebersbach et al.4 and it clearly 
seems to be due to a placebo effect. 
Our results come from a protocol where PD patients were evaluated during ON and OFF periods, and 
in both situations results followed the same pattern, so that it seems this effect (placebo) does not depend 
on the regime of medication. Of course there are more variables to be taken into account, (for instance the 
stimulation frequency or the number of sessions), but our results seem to show that vibration has not an 
effect “per se,” as the same results were seen without vibration. 
The repeated measures analysis of variance model used in this study is appropriate to the dataset and, 
overall, the approach employed is valid with adequate groups sizes (10 and 11 for experimental and 
placebo respectively) for pre post analysis. However the sample size for the inter-session analyses is 
limited with a strong drop in power. This represents a limitation of the study and it is due to the relative 
lack of increasing power with repeated measures above 7 observations (see for instance Rochon12 and 
Vickers13). However, we like to point out that this happens only in 2 of 14 variables analyzed (TUG and 
FR during ON dose, which were evaluated everyday), which, on the other hand, followed the same 
pattern of change than all the others. 
In conclusion, we suggest that future studies regarding WBV should consider the possibility of a 
placebo effect in the design of paradigms involving Parkinsonian patients. 
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